UNSPSC 51401548: Reclazepam

This classification denotes an anxiolytic with the molecular formula C18H13Cl2N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YJL42911RA, chemically known as 4(5h)-oxazolone, 2-(7-chloro-5-(2-chlorophenyl)-2,3-dihydro-1h-1,4-benzodiazepin-1-yl)-; but generally known as reclazepam, which bears US NIH Compound Identifier 3052777. European Medicines Agency schedules Reclazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10269MIG.

UNSPSC 51401548 Reclazepam is a Commodity code that in practice encompasses pharmaceutical procurement by state and local health agencies, though recent solicitations under this code are sparse and diverge significantly from the nominal product. State and local governments soliciting under this code are purchasing naloxone and drug deactivation systems for community health programs, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing alliances, and exploring direct-to-manufacturer prescription fulfillment models. The issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing organizations. Procurement typically follows IFB, RFP, and RFI notice types, with vendors required to comply with federal manufacturing and supply-chain security standards (FDA, cGMP, DSCSA), maintain substantial insurance coverage, and submit pricing through dedicated e-procurement portals or spreadsheet-based submission systems.

Recent activity is concentrated in Florida and Texas, with multistate cooperative purchasing reaching across jurisdictions including Minnesota and Oregon. A representative recent opportunity is Seminole County, Florida's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, fixed-fee pricing, and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026, due April 3, 2026) represents exploratory procurement for direct-to-manufacturer prescription programs to serve self-insured health plans and state agencies. The Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products (due March 26, 2026) illustrates the cooperative vehicle commonly used to aggregate purchasing across multiple states and local jurisdictions, with awarded vendors distributed through three authorized wholesalers and resulting contracts effective July 1, 2026.